Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Levomecor Inc.
This is an outpatient, 2-arm, Phase 3, multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of REL-1017 once daily (QD) as an adjunctive treatment of Major Depressive Disorder in patients with inadequate response to ongoing background antidepressant treatment. Eligible patients will continue to take their background antidepressant therapy and be randomized in a 1:1 ratio to treatment with REL-1017 or placebo for a 4 week treatment period.
Age
18–65
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Body mass index (BMI) between 18.0 and 35.0 kg/m2.
Diagnosed with Major Depressive Disorder (MDD) based on Structured Clinical Interview for DSM-5 (SCID-5) for MDD.
Inadequate response to 1 to 3 adequate antidepressant treatments in the current MDE.
You may not be if
Psychiatric hospitalization during the current major depressive episode.
History or presence of clinically significant health conditions which in the opinion of the Investigator would negatively impact the safety of the participant.
Participants who, in the Investigator's judgment, are at significant risk for suicide.